Literature DB >> 19636205

N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with Type 2 diabetes mellitus.

A Masha1, L Brocato, S Dinatale, C Mascia, F Biasi, V Martina.   

Abstract

UNLABELLED: Post-prandial hyperglycemia seems to play a pivotal role in the pathogenesis of the cardiovascular complications of diabetes mellitus, as it leads to an oxidative stress which in turn causes a reduced NO bioavailability. These conditions produce an endothelial activation. AIM OF THE STUDY: The aim of this study was to assure that the administration of N-acetylcysteine (NAC), thiolic antioxidant, is able to decrease the oxidation status and endothelial activation after a high-glucose content meal. SUBJECTS AND METHODS: Ten patients with Type 2 diabetes mellitus (DMT2) (Group 1) and 10 normal subjects (Group 2) were studied. They assumed a high-glucose content meal without (phase A) or after (phase B) the administration of NAC. Glycemia, insulinemia, intercellular adhesion molecule 1, vascular adhesion molecule 1 (VCAM-1), E-selectin, malonaldehyde (MDA), and 4-hydroxynonenal (HNE) were assessed at -30, 0, +30, +60, +90, +120, and +180 min with respect to the meal consumption.
RESULTS: During the phase A in Group 1, only HNE and MDA levels increased after the meal assumption; all parameters remained unchanged in Group 2. During the phase B, in Group 1, HNE, MDA, VCAM-1, and E-selectin levels after the meal were lower than those in phase A, while no change for all variables were observed in Group 2.
CONCLUSIONS: A high-glucose meal produces an increase in oxidation parameters in patients with DMT2. The administration of NAC reduces the oxidative stress and, by doing so, reduces the endothelial activation. In conclusion, NAC could be efficacious in the slackening of the progression of vascular damage in DMT2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636205     DOI: 10.1007/BF03345726

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

Review 1.  Regulation of nitric oxide-sensitive guanylyl cyclase.

Authors:  Andreas Friebe; Doris Koesling
Journal:  Circ Res       Date:  2003-07-25       Impact factor: 17.367

Review 2.  Nitric oxide and the endothelium: history and impact on cardiovascular disease.

Authors:  Gunay Yetik-Anacak; John D Catravas
Journal:  Vascul Pharmacol       Date:  2006-08-17       Impact factor: 5.773

Review 3.  Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function.

Authors:  S Moncada; M W Radomski; R M Palmer
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

4.  Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds.

Authors:  L J Ignarro; J C Edwards; D Y Gruetter; B K Barry; C A Gruetter
Journal:  FEBS Lett       Date:  1980-02-11       Impact factor: 4.124

Review 5.  Nitric oxide and atherosclerosis.

Authors:  C Napoli; L J Ignarro
Journal:  Nitric Oxide       Date:  2001-04       Impact factor: 4.427

Review 6.  Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.

Authors:  E Bonora; M Muggeo
Journal:  Diabetologia       Date:  2001-12       Impact factor: 10.122

7.  Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1.

Authors:  V Martina; G A Bruno; E Zumpano; C Origlia; L Quaranta; G P Pescarmona
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

8.  Nitric oxide prevents inducible cyclooxygenase expression by inhibiting nuclear factor-kappa B and nuclear factor-interleukin-6 activation.

Authors:  F D'Acquisto; M C Maiuri; F de Cristofaro; R Carnuccio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-08       Impact factor: 3.000

9.  Platelet cNOS activity is reduced in patients with IDDM and NIDDM.

Authors:  V Martina; G A Bruno; F Trucco; E Zumpano; M Tagliabue; C Di Bisceglie; G Pescarmona
Journal:  Thromb Haemost       Date:  1998-03       Impact factor: 5.249

10.  Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes.

Authors:  Valentino Martina; Andi Masha; Valentina Ramella Gigliardi; Loredana Brocato; Enzo Manzato; Arrigo Berchio; Paola Massarenti; Fabio Settanni; Lara Della Casa; Stefania Bergamini; Anna Iannone
Journal:  Diabetes Care       Date:  2008-02-11       Impact factor: 19.112

View more
  9 in total

1.  The antioxidant N-Acetylcysteine does not improve glucose tolerance or β-cell function in type 2 diabetes.

Authors:  Magdalena A Szkudlinska; Anize D von Frankenberg; Kristina M Utzschneider
Journal:  J Diabetes Complications       Date:  2016-02-05       Impact factor: 2.852

2.  N-Acetylcysteine Enhances the Recovery of Ischemic Limb in Type-2 Diabetic Mice.

Authors:  Qiang Zhu; Xuanyou Liu; Qingyi Zhu; Zehao Liu; Chunlin Yang; Hao Wu; Linfang Zhang; Xiujuan Xia; Meifang Wang; Hong Hao; Yuqi Cui; Guangsen Zhang; Michael A Hill; Gregory C Flaker; Shenghua Zhou; Zhenguo Liu
Journal:  Antioxidants (Basel)       Date:  2022-05-31

3.  N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial.

Authors:  A T Treweeke; T J Winterburn; I Mackenzie; F Barrett; C Barr; G F Rushworth; I Dransfield; S M MacRury; I L Megson
Journal:  Diabetologia       Date:  2012-08-31       Impact factor: 10.122

4.  Ginkgo biloba extract reduces high-glucose-induced endothelial adhesion by inhibiting the redox-dependent interleukin-6 pathways.

Authors:  Jia-Shiong Chen; Yung-Hsiang Chen; Po-Hsun Huang; Hsiao-Ya Tsai; Yuh-Lien Chen; Shing-Jong Lin; Jaw-Wen Chen
Journal:  Cardiovasc Diabetol       Date:  2012-05-03       Impact factor: 9.951

5.  Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes.

Authors:  Kyle R Gibson; Tim J Winterburn; Fiona Barrett; Sushma Sharma; Sandra M MacRury; Ian L Megson
Journal:  Cardiovasc Diabetol       Date:  2011-05-21       Impact factor: 9.951

6.  Activation of Nrf2-mediated anti-oxidant genes by antrodin C prevents hyperglycemia-induced senescence and apoptosis in human endothelial cells.

Authors:  Kumar K J Senthil; Vani M Gokila; Sheng-Yang Wang
Journal:  Oncotarget       Date:  2017-08-04

Review 7.  Thiol signalling network with an eye to diabetes.

Authors:  Elena Matteucci; Ottavio Giampietro
Journal:  Molecules       Date:  2010-12-06       Impact factor: 4.411

Review 8.  Preventing the development of severe COVID-19 by modifying immunothrombosis.

Authors:  Gerwyn Morris; Chiara C Bortolasci; Basant K Puri; Lisa Olive; Wolfgang Marx; Adrienne O'Neil; Eugene Athan; Andre Carvalho; Michael Maes; Ken Walder; Michael Berk
Journal:  Life Sci       Date:  2020-10-20       Impact factor: 5.037

Review 9.  Endothelial Glycocalyx as a Regulator of Fibrotic Processes.

Authors:  Valentina Masola; Gianluigi Zaza; Arduino Arduini; Maurizio Onisto; Giovanni Gambaro
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.